There are currently 29 active clinical trials seeking participants for Non-Alcoholic Fatty Liver Disease research studies. The states with the highest number of trials for Autism participants are Texas, California, Florida and North Carolina.
Assessment of Fatty Liver With Thermo-acoustic Device
NCT04302051
Recruiting
The study will evaluate the accuracy of hepatic steatosis estimation by thermo-acoustic ultrasound with estimation by MRI-PDFF (Proton Density Fat Fraction) . It will also evaluate the sensitivity of this device in the diagnosis of fatty liver.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
03/02/2024
Locations: Froedtert Hospital, Milwaukee, Wisconsin
Conditions: NASH, NAFLD, Non-alcoholic Fatty Liver, Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Fatty Liver, Fatty Liver Disease
Register for Updates
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
NCT03884075
Recruiting
Background: In non-alcoholic fatty liver disease (NAFLD), fat accumulates in the liver and can cause damage. Researchers want to learn what causes the damage NAFLD, and to see if a medication can help. Objective: To find out how the liver in people with NAFLD responds to feeding, and how this relates to their response to the drug semaglutide. Eligibility: People with NAFLD and healthy volunteers ages 18 and older Design: Participants will be screened with: Medical history Physical exam... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/17/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Non-Alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease
Register for Updates
Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease
NCT06176079
Recruiting
The recent development of dissolution dynamic nuclear polarization (DNP) technology for hyperpolarized (HP) 13C imaging offers a promising new avenue for non-invasively accessing fundamental metabolic changes associated with the progression of fatty liver disease in vivo. The purpose of this pilot study is to optimize sequence parameters for hyperpolarized 13C acquisition in the human liver and determine which metabolic changes can be seen in humans with simple, non-alcoholic fatty liver disease... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/10/2023
Locations: University of California, San Francisco, San Francisco, California
Conditions: Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non Alcoholic Steatohepatitis, NAFLD, NASH
Register for Updates
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
NCT04951219
Recruiting
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Central Research Associates, Birmingham, Alabama +73 locations
Conditions: Non-Alcoholic Fatty Liver Disease
Register for Updates
Super HEROES: Searching How the Extract Rebaudioside Occludes Excess Steatosis
NCT03985020
Recruiting
In order to determine whether rebaudioside consumption can be used as a treatment for adolescents with Non-alcoholic Fatty Liver Disease (NAFLD) by demonstrating a decrease in alanine aminotransferase (ALT) levels participants will be randomized to receive one of three 8-week liquid diet interventions: Standard of care Water delivery Water with Rebaudioside (stevia natural sweetener)
Gender:
All
Ages:
Between 10 years and 18 years
Trial Updated:
11/02/2023
Locations: Children's Hospital of Los Angeles, Los Angeles, California
Conditions: Non-Alcoholic Fatty Liver Disease
Register for Updates
Healthy Liver - Healthy Brain
NCT05216796
Recruiting
People with liver disease report difficulties with attention and problem-solving skills. Diet plays an important role in the development of liver disease and/or pre-diabetes. The purpose of this study is to examine whether participation in a brief diet intervention (up to 3 weeks) can improve brain and liver health and function.
Gender:
All
Ages:
40 years and above
Trial Updated:
10/27/2023
Locations: University of Texas at Austin, Austin, Texas
Conditions: Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease, NAFLD, Pre-diabetes
Register for Updates
A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)
NCT06007651
Recruiting
The main purpose of this study is to evaluate the safety and tolerability of LY3885125 after administration of single ascending doses in participants with dyslipidemia (part A) and multiple doses in participants with non-alcoholic fatty liver disease (part B). Blood tests will be performed to check how much LY3885125 gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 49 weeks for part A and 62 weeks for part B, for a total of approx... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
10/17/2023
Locations: Worldwide Clinical Trials, Early Phase Services LLC, San Antonio, Texas
Conditions: Dyslipidemias, Non-Alcoholic Fatty Liver Disease
Register for Updates
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
NCT05464784
Recruiting
The design of the Phase 2 clinical trial includes the following elements: Multi-center, two-arm, randomized, double-blind, placebo-controlled trial to evaluate MN-001 (tipelukast) vs. placebo in approximately 40 patients in the U.S. Patients will be randomized 1:1 to receive either 500 mg/day of MN-001 (tipelukast) or placebo for 24 weeks. The co-primary endpoints are (1) change from baseline in liver fat content measured by controlled attenuation parameter (CAP) score at Week 24, and (2) chang... Read More
Gender:
All
Ages:
Between 21 years and 75 years
Trial Updated:
09/27/2023
Locations: Jubilee Clinical Research, Inc., Las Vegas, Nevada
Conditions: Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease
Register for Updates
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
NCT05067621
Recruiting
The purpose of this study is to understand the role of GLP-1 in the pathogenesis of T2D in youth and explore their potential salutary effects and ability to delay the progressive loss of ß-cell function and reduce hepatic steatosis in youth with prediabetes/new onset T2D and NAFLD.
Gender:
All
Ages:
Between 10 years and 21 years
Trial Updated:
09/11/2023
Locations: Pediatric Diabetes Center, New Haven, Connecticut
Conditions: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease, Obesity, Childhood
Register for Updates
Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM
NCT06005012
Recruiting
Conduct a community intervention study that will 1) validate a screening approach to identify patients at risk for advanced NAFLD in the obese or T2DM population, and 2) test whether semaglutide treatment is effective for the management of significant fibrosis due to NAFLD in high-risk patients.
Gender:
All
Ages:
Between 40 years and 79 years
Trial Updated:
09/01/2023
Locations: University of California, San Diego, La Jolla, California
Conditions: Fibrosis, Liver, Type 2 Diabetes Mellitus in Obese, Non-Alcoholic Fatty Liver Disease
Register for Updates
Quantifying Hepatic Mitochondrial Fluxes in Humans
NCT05305287
Recruiting
In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
08/21/2023
Locations: Texas Diabetes Institute - University Health System, San Antonio, Texas +1 locations
Conditions: Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes, Mitochondrial Metabolism Disorders
Register for Updates
AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
NCT04807868
Recruiting
The purpose of this study is to create a resource that will advance research that is focused on discovery of novel therapies, risk stratification, and aggressive interventions for those at highest risk for non-alcoholic fatty liver disease (NAFLD). To achieve this, we will generate a biobank of liver tissue collected during standard of care liver biopsies. Paired blood/urine samples, FibroScan and relevant data will also be collected.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2023
Locations: AdventHealth Translational Research Institute, Orlando, Florida
Conditions: Non-Alcoholic Fatty Liver Disease
Register for Updates